Introduction
Vaccination is a proven and one of the most cost-effective child survival interventions. All countries in the world have an immunization programme to deliver selected vaccines to the targeted beneficiaries, specially focusing on pregnant women, infants and children, who are at a high risk of diseases preventable by vaccines. There are at least 27 causative agents against which vaccines are available and many more agents are targeted for development of vaccines the number of antigens in the immunization programmes varies from country to country; however, there are a few selected antigens against diphtheria, pertussis, tetanus, poliomyelitis, measles, hepatitis B which are part of immunization programmes in most of the countries in the world. UIP was given the status of a National Technology Mission in 1986. A specific Immunization Strengthening Project (ISP) was designed to run from 2000-2003, which included three main components (polio eradication, strengthening routine immunization, and strategic framework for development).
Vaccination is a proven and one of the most cost-effective child survival interventions. All countries in the world have an immunization programme to deliver selected vaccines to the targeted beneficiaries, specially focusing on pregnant women, infants and children, who are at a high risk of diseases preventable by vaccines. There are at least 27 causative agents against which vaccines are available and many more agents are targeted for development of vaccines the number of antigens in the immunization programmes varies from country to country; however, there are a few selected antigens against diphtheria, pertussis, tetanus, poliomyelitis, measles, hepatitis B which are part of immunization programmes in most of the countries in the world.
UIP was given the status of a National Technology Mission in 1986. A specific Immunization Strengthening Project (ISP) was designed to run from 2000-2003, which included three main components (polio eradication, strengthening routine immunization, and strategic framework for development).
The overarching goal of the UIP is to reduce morbidity and mortality due to vaccine preventable diseases (VPD). While surveillance information for specific VPDs is limited, the steady fall of IMR from 123 to 50 deaths per 1000 live-births (SRS 2011) does in part reflect the impact of the UIP. Besides, in the past 15 years, a decline in the reported number of cases of the main VPDs (diphtheria, tetanus, pertussis and measles) has been observed. The same data though does show an increase in the number of reported measles, diphtheria and pertussis cases in recent years with measles continuing to be responsible for 6% of childhood mortality or 80,000 deaths annually. Since its launch in 1995, the Polio Pulse campaign aimed at eradicating polio from India, has begun to show results. Government efforts have brought India closer to the goal of polio eradication than ever before in history with only 42 confirmed cases in 2010 and only one in 2011.
As a part of the broader National Health Policy, a national vaccine policy is needed, based on the principles of public health and comprehensive primary health care. This is to enable rational and evidence-based decisions for the development, entry, production, stable supply, pricing, promotion and use of appropriate vaccines on scientific grounds. Additionally, this is also needed to protect the national vaccine programmes and national health security, as well as to leverage indigenous capabilities to cater to domestic and overseas markets. 
Objectives of the national vaccine policy

To synergize all relevant policies for effective implementation of the national vaccine policy
The national policy of immunization under Universal Immunisationprogramme is phased in manner as seen in following table:
UIP in India and its core antigens have made a significant impact on the burden of diseases in the country and directly contributed to reducing child mortality. There is limited production capacity of these vaccines in public sector units and the involvement of private sector manufacturers is required to ensure that supply of UIP vaccine is not threatened.
For new and under utilized vaccines, there is need for the institutionalizing and strengthening of decision making process in-built country mechanism for sustainable production of newer vaccines within country.
India has a leading vaccine industry; however, there is need for investing more on the research for the vaccines for the priority diseases in the country.
For potentially new vaccines and vaccine security issues, the implementation of immunization program should be put in the perspective of broader goals of National Health Policy. The sufficient political will & support, and financing mechanisms should also be ensured for this purpose.
Situation analysis:India's vaccine industry ranks third in terms of volume globally in the world. The impact of vaccination suggest that IMR in India had fallen steadily to reach 40 deaths per 1000 live-birth as per Sample Registration System in 2013, while as per Sample Registration System 2012 it was 52 per 1000 live births.National vaccination coverage is believed to be around 72%. However, there are major differences in coverage among the states, ranging from below 30% to above 90% in some states. The private health sector provides an estimated 15-20% of immunization services.14 states with measles coverage< 80% -(Arunanchal Pradesh, Assam, Bihar, Chattisgarh, Gujarat, Haryana, Jharkhand, M.P, Manipur, Meghalaya, Nagaland, Rajasthan, Tripura and U.P).In the remaining 21 states with better performing routine immunization systems (i.e.,>=80% routine measles coverage).
It has been three years without any fresh cases of Polio; India has officially eliminated the much dreaded disease effective January 2014.
The elimination of maternal and neonatal tetanus comes a year after India eradicated polio. Maternal and neonatal tetanus is now reduced to less than one case per 1 000 live births in all 675 districts of the country.
Haemophilusinfluenzae type b (Hib) vaccines, Pneumococcal conjugate vaccines, Rotavirus vaccines, HPV vaccines, which have estimated reducing child mortality in India.
Barriers to strengthen Immunization Programme:
There are well recognized challenges in the implementation of immunization program in the country as follows: Weak VPD surveillance system;
Lack of data on disease burden in India
Lack of diagnostic tools and specialized training for certain VPD.
Lack of baseline surveillance data.
Limited economic evaluations
Lack of a financial sustainability plan for the introduction of new vaccines. Creation of Bio-repositories :Biorepository is a confidential list of people who are willing to participate in a vaccine study, have had a virus or who have lived in a Dengue virus risk area and are willing to participate in one of our studies.
Banking of biological samples both sera and organisms that are collected during diseases surveillance, epidemics or clinical trials can be a tremendous source of materials for retrospective use in case of re-emergence of a disease.Administration, management, custodianship, and security of biobanks can be major issues.
The existing guidelines that govern the functioning of a National Biorepository in India and the best practices followed in other countries should be examined and an India specific Standard Operating Procedure and Guidelines needs to be drafted with appropriate linkages with different programs.
The concept of public private partnership (PPP) has aided in bridging the gaps between academia, industry, and funding agencies successfully. The PPPs have also evolved innovative methods for intellectual property and portfolio management, and has unique structures and methods for governance. unequivocally established in India with sound epidemiological and cost-benefit data. Therefore, India (and indeed, every country) must evolve its own national strategies to meet its vaccination needs within its budgetary constraints. To do so will require following are key actions.The first and foremost element is the decisive intervention of the Indian government to meet the shortfall in the UIP vaccines. Secondly, India needs to strengthen epidemiology and revive the collapsing disease surveillance system. Thirdly, a strong emphasis on in-house R&D is needed.Lastly, the Indian government should actively encourage independent policy research, cost-benefit studies, and wider national consultations
An indigenous new generation Oral Cholera Vaccine has also been brought to the market with the partners being
The new logo of the baby holding the syringe,indicating RI as his right, has been developed in purple color. This will give RI a distinct identity. Deliberate effortshave been made to stay away from the Polio brand colors of yellow and pink.
Vaccine wastage :An assessment of vaccine wastage in India, conducted in 2009 revealed that wastage rates depended on formulation, presentation and was inversely proportional to session size. Both cold chain requirement and vaccine wastage is expected to increase several fold with the introduction of newer vaccines compared to the UIP vaccines.
Following table shows wastage of six vaccines commonly used in the programme, which are administered according to the national immunization schedule.
Use of phase change materials (PCMs) can help reduce vaccine wastage during transportation. The present size of immunization division is extremely small, given the size of the country and number of beneficiaries to be serviced. Capacity building needs to be supported on a sustainable basis and should be adequately stressed in the national budget.
CONCLUSIONS AND RECOMMENDATIONS
India enjoyed the advantages of early initial successes in vaccine R&D and indigenous production in the public sector, but the country is increasingly unable to cope with the growing gap in the demand and supply of UIP vaccines . The availability of UIP vaccines from the private sector is also on the decline in India and abroad, in favour of more expensive new vaccines and combination vaccines, whose public health need has not been
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